Tag: TNBC
-
Kazia Therapeutics Reports Encouraging Early Signals from Paxalisib + Pembrolizumab in Late-Stage Metastatic TNBC
Overview of the Update Kazia Therapeutics (NASDAQ: KZIA) announced an interim clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage (Stage IV) metastatic triple-negative breast cancer (TNBC). The release underscores encouraging preliminary clinical responses observed to date, reinforcing interest in paxalisib as part of…
-
Kazia Therapeutics Unveils Encouraging Early Responses for Paxalisib in Late-Stage TNBC
Overview of the Phase 1b Study Kazia Therapeutics has announced encouraging preliminary clinical responses from its ongoing Phase 1b trial evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage, Stage IV triple-negative breast cancer (TNBC). The study explores paxalisib, an AKT inhibitor, as part of a multi-agent regimen designed to address the…
-
Kazia Therapeutics Reports Encouraging Early Signals for Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Overview of the Phase 1b Study Kazia Therapeutics (NASDAQ: KZIA) announced encouraging early clinical responses from its ongoing Phase 1b trial evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage, metastatic triple-negative breast cancer (TNBC). The update signals potential activity for paxalisib, a PI3K/AKT/mTOR pathway inhibitor, when combined with standard immuno-oncology and…
-
MRI May Predict Outcomes in TNBC Treatment with Chemo and Immunotherapy
Overview: MRI as a Tool in TNBC Treatment Triple-negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes to treat. Recent research suggests that magnetic resonance imaging (MRI) may play a pivotal role in predicting how patients with TNBC will respond to a combination of neoadjuvant chemotherapy and immunotherapy. This could lead…
-
MRI May Predict Outcomes in TNBC Treatment with Neoadjuvant Chemo and Immunotherapy
Understanding the New Findings Triple-negative breast cancer (TNBC) remains a challenging subtype of breast cancer, characterized by the absence of estrogen, progesterone, and HER2 receptors. This makes targeted hormonal therapies ineffective, driving interest in combination approaches such as neoadjuvant chemotherapy paired with immunotherapy. Recent research suggests that magnetic resonance imaging (MRI) could play a pivotal…
-
Study Finds MRI Could Help Predict Outcomes in Triple-Negative Breast Cancer Treatment
Overview: MRI in the Era of Chemo-Immunotherapy for TNBC Triple-negative breast cancer (TNBC) is a challenging subtype that often requires aggressive treatment. Recent studies indicate that magnetic resonance imaging (MRI) may play a valuable role in predicting how patients with TNBC will respond to a combination of neoadjuvant chemotherapy and immunotherapy. This potential diagnostic aid…
-
Study Uncovers Therapeutic Vulnerability in Aggressive Subtype of Triple-Negative Breast Cancer
Groundbreaking finding in a difficult cancer subtype A new study published in Science Translational Medicine from researchers at The University of Texas MD Anderson Cancer Center identifies a previously unrecognized therapeutic vulnerability in an aggressive subtype of triple-negative breast cancer (TNBC). The work, led by Dr. Khan and a multidisciplinary team, focuses on molecular drivers…
-
Therapeutic Vulnerability Uncovered in Aggressive Triple-Negative Breast Cancer Subtype
Breakthrough in Aggressive TNBC Subtype A landmark study published in Science Translational Medicine reveals a previously unrecognized therapeutic vulnerability in an aggressive subtype of triple-negative breast cancer (TNBC). Conducted by researchers at The University of Texas MD Anderson Cancer Center, the work provides new insight into how this hard-to-treat cancer might be targeted more effectively…
-
Therapeutic vulnerability uncovered in aggressive triple-negative breast cancer
Overview of the finding A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center reports a previously unrecognized therapeutic vulnerability in an aggressive subtype of triple-negative breast cancer (TNBC). Led by a team including Dr. Khan, the study identifies a molecular weakness that could be exploited…
-
Interplay of lncRNAs and MAPK Signaling in Breast Cancer Pathogenesis
Overview: lncRNAs and the MAPK Signaling Web in Breast Cancer Breast cancer pathogenesis is shaped by intricate signaling networks, with MAPK pathways acting as central hubs that govern proliferation, survival, migration, and angiogenesis. Long non-coding RNAs (lncRNAs) have emerged as influential regulators of these cascades, operating as molecular sponges, scaffolds, and downstream effectors. This article…